Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| BioMérieux | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Bacteremia is a frequent infection in intensive care units. It is associated with a high mortality rate and the rapid implementation of appropriate antibiotic therapy is strongly correlated to patient clinical outcomes.
Innovative technologies have emerged to shorten the turnaround time of blood culture samples by obtaining susceptibility testing of the incriminated pathogen at an early stage, and therefore to rapidly adjust the antibiotic therapy of patients with Gram-negative Bacilli bacteremia.
The study investigators hypothesize that the implementation of the innovative BacT/Alert® VIRTUO®, BioFire® BCID2 and REVEAL® solutions for the analysis of blood culture samples will increase the proportion of patients with Gram-negative Bacilli bacteremia who receive appropriate and optimized antibiotic therapy 24 hours after blood culture collection.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| After innovative diagnostic technologies | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Innovative diagnostic technologies | Diagnostic Test | Samples from patients positive for Gram-negative bacteremia will be analyzed using the new BacT/Alert® VIRTUO®, BioFire® BCID2 and REVEAL® diagnostic solutions |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of patients receiving optimized antibiotic therapy (adequate and narrowest spectrum antibiotic therapy) in patients with Gram-negative bacteremia 24 hours after blood culture samples | Yes/no: receiving optimized antibiotic therapy (effective and narrowest spectrum for the identified pathogen(s)) 24 hours after blood culture collection, before and after implementation of the new diagnostic solutions | 24 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Time to adapt antibiotic therapy (optimized) based on susceptibility testing between the two periods of the study (before and after the implementation of innovative diagnostic technologies) following the collection of blood cultures | Hours (theoretical and real) between blood culture collection and the first change in antibiotic therapy based on the innovative diagnostic technologies solutions or the conventional susceptibility test |
Not provided
Inclusion Criteria:
For the 'after' section of the study only:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Alix Pantel | CHU de Nimes | Principal Investigator |
| Claire Roger | CHU de Nimes | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Nîmes | Nîmes | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40754712 | Result | Oudiane L, Benyahia M, Salipante F, Dubois A, Muller L, Lavigne JP, Pantel A, Roger C. Clinical impact of the BCID2 and rapid AST VITEK(R) REVEALTM on antibiotic optimisation in critically ill patients with Gram-negative bloodstream infections: a quasi-experimental pre/post interventional study. J Antimicrob Chemother. 2025 Oct 3;80(10):2665-2675. doi: 10.1093/jac/dkaf271. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Reference diagnostic technique | Diagnostic Test | Analysis of samples using diffusion on Mueller Hinton (MH) agar medium according to EUCAST. |
|
| 28 Days |
| Concordance of the REVEAL® rapid antibiotic susceptibility testing technology with reference methods | Categorical Agreement of antibiotics tested by REVEAL® technology compared to the reference method (agar plate susceptibility test) | 28 Days |
| Patient survival | Vital status of patients | 28 Days |
| Length of stay in intensive care unit | Number of days | 28 Days |
| Prevalence rate of multiresistant bacteria between the "before" and "after" periods | Proportion of multiresistant bacteria in each evaluation period | 28 Days |
| Prevalence rate of bacteria which are highly resistant to emerging antibiotics between the "before" and "after" periods | Proportion of bacteria which are highly resistant to emerging antibiotics in each evaluation period | 28 Days |
| cost of the device for the healthcare facility | purchase price of the equipment, depreciation, consumables, additional human time if applicable | 28 Days |
| Compare the amount per patient from the health insurance point of view. | amount associated with the number of days spent in intensive care | 28 Days |
| ID | Term |
|---|---|
| D016470 | Bacteremia |
| ID | Term |
|---|---|
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
| D018805 | Sepsis |
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided